FDA Draft Guidance Covers New Discipline Review Letters Added by GDUFA II

Drug Industry Daily
The FDA outlined how it will use information requests and the newly established discipline review letter — which originates from specialized staff concerning their portion of an ANDA review, such as bioequivalence, quality or labeling.

To View This Article:


Subscribe To Drug Industry Daily